Biofrontera AG has announced a binding agreement with Biofrontera Inc. to ensure the long-term continuity of its business operations in the United States. As part of the transaction, Biofrontera AG will receive a 10% stake in Biofrontera Inc., along with ongoing royalty payments of 12% to 15% on U.S. sales of Ameluz®. The agreement also includes a one-year lock-up commitment by Biofrontera Inc., prohibiting further dilutive capital increases without prior consent from Biofrontera AG. Effective June 1, 2025, all assets and liabilities related to the commercialization of Ameluz® in the U.S. will be transferred to Biofrontera Inc. This strategic restructuring aims to reduce risks and costs for Biofrontera AG while ensuring a stable financial basis for Biofrontera Inc.'s U.S. activities through an $11 million financing round supported by investors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.